+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Carrier Screening Market By Technology, By End user, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

  • PDF Icon

    Report

  • 193 Pages
  • November 2021
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5514551

The Global Carrier Screening Market size is expected to reach $2,501.94 million by 2027, rising at a market growth of 10.81% CAGR during the forecast period.

Carrier screening refers to a type of testing procedure that allows an end-user to know if he/she has a gene for any kind of genetic disorder. Carrier screening is broadly implemented before/during pregnancy for preventing the possibility of passing the disease to the newborn. It is suggested to both the parents go through carrier screening, as the possibility of forwarding the genetic disease grows if the two parents are the carriers of any sort of genetic defect. Factor such as massive adoption of carrier screening before and during pregnancy, due to the rise in awareness regarding the adverse effects associated with the passing of genetic diseases is expected to acts as a growth factor for carrier screening market during the forecast period.

The rise in awareness regarding the possibility of transferring the genetic diseases is seen in the healthcare sector among the end-users. To tackle this, end-users have become more careful, with a desire to detect and avoid these diseases at their early phase. These factors are anticipated to boost the growth and demand for the carrier screening market during the forecast period. In the last couple of years, the overall carrier screening market has seen huge popularity due to its advantages. Moreover, the adoption rate of carrier screening and testing is expected to increase due to the rise in the number of patients with genetic disorders.





COVID-19 Impact Analysis

The onset of the COVID-19 pandemic was in the Wuhan city of China. The disease is occurred by a virus, extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transferred among humans. Since the beginning of the virus in Wuhan, the disease increasingly spread to other regions of the world. In addition, this virus causes several symptoms in patients, which may vary from common symptoms to severe symptoms. For example, common symptoms may include dry cough, fever, and fatigue. Though, several symptoms include problems in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement.

Moreover, the virus has the massive potential of mortality in a geriatric population. In March 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and health emergency. Additionally, there are only some vaccines that got emergency approvals for the treatment and prevention of COVID-19. Hence, social distancing is considered the most effective step to curb the spread of the deadly virus. Further, numerous countries globally have embraced stringent lockdown conditions to maintain social distancing norms.



Market Growth Factors:

Well-established Healthcare Infrastructure

Many countries are focusing on building sophisticated healthcare infrastructure which is equipped with advanced screening and treatment procedures. In addition, nations in the developed countries have advanced healthcare infrastructure, which are integrated with different types of carrier screening procedures, thereby propelling the growth and demand for carrier screening techniques across such countries. Moreover, many individuals want to know the possibility of transmission of their genetic or hereditary diseases to their offerings. Therefore, these factors are anticipated to unlock bright growth prospects for the players operating in the overall carrier screening market during the forecasting period.



Increasing cases of genetic diseases

The demand and growth of the carrier screening market is expected to be fueled by the increase in the prevalence of genetic diseases around the globe. This is due to the possibility and severity of these diseases based on the carrier status of parents and their ancestors. The American College of Obstetricians and Gynecologists suggests the testing of all pregnant women and those thinking of motherhood in the near future to recognize the possibilities of these illnesses, specifically cystic fibrosis, fragile X syndrome, and spinal muscular atrophy (SMA), at an early stage.



Marketing Restraining Factor:

Low awareness and lack of trained professionals

As cell therapies are gaining more popularity, the automated processing systems market needs more skilled professionals to carry out these therapies and operate automated systems. However, the dearth of skilled professionals is estimated to hinder the growth of the Carrier Screening Market over the forecast period. In addition, the usage of technologically advanced and highly complicated flow cytometers and spectrophotometers for generating a huge amount of data outputs require knowledge for interpreting and reviewing is expected to hinder the market growth.





Type Outlook

Based on carrier screening type, the market is segregated into expanded carrier screening and targeted disease carrier screening. The expanded carrier screening segment procured the maximum revenue share of the overall carrier screening market in 2020. This is credited to the constant development in a polymerase chain reaction, sequencing, microarrays, and other similar technologies in the domain of carrier screening. In addition, the market is likely to witness new growth avenues due to the rising cases of genetic disorders.



Technology Outlook

Based on technology, the carrier screening market is divided into DNA sequencing, microarrays, polymerase chain reaction, and other technologies. In 2020, the DNA sequencing segment acquired the largest revenue share of the overall carrier screening market. The segment is expected to emerge as the leading segment during the forecasting period. This is credited to the constant developments in genetic analysis tools, like assays built on next-generation sequencing and microarray technologies, molecular diagnostics, and advancing the kind for heritable disorders.



End-User Outlook

Based on end-user, the market is segmented into hospitals & clinics, reference laboratories, physician offices, and others. The hospital & clinics segment garnered the largest revenue share in the overall carrier screening market in 2020. Moreover, the segment is likely to showcase a similar kind of trend even during the forecast period. Factors such as the growing occurrence of genetic disorders and developments in carrier screening are likely to propel the growth of this segment.



Regional Outlook

Based on the Region, the carrier screening market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America emerged as the leading region by obtaining the biggest revenue share of the overall carrier screening market in 2020. Moreover, the regional market is expected to showcase a similar kind of trend even during the forecast period. Factors such as the rising occurrence of pulmonary conditions, hematological conditions, and neurological conditions in the region are responsible for the massive growth of the regional market.



Cardinal Matrix - Carrier Screening Market Competition Analysis



The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific is the forerunner in the Carrier Screening Market. Companies such as Quest Diagnostics, Eurofins Scientific, Illumina, Inc. are some of the key innovators in Carrier Screening Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics, Incorporated, Thermo Fisher Scientific, Illumina, Inc., Eurofins Scientific Group, Invitae Corporation, OPKO Health, Inc., Fulgent Genetics, Sema4 OpCo, Inc., Myriad Genetics, Inc., and Natera, Inc.



Recent Strategies Deployed in Carrier Screening Market

Partnerships, Collaborations and Agreements:

  • May-2021: Illumina collaborated with Next Generation Genomic, an association of the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science. Through this collaboration, the two entities introduced VeriSeq NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT).
  • Mar-2021: Natera joined hands with Tesis Labs, a US multi-region lab services provider with labs in Colorado, Texas, and Arizona. The collaboration aimed to enable Tesis to widen its portfolio of genetic testing offerings and participate in the fast-growing screening market of above 4 million pregnancies across the US. Moreover, the ultra-modern and extremely scalable genetics laboratory of Tesis in Lafayette, Colorado can serve many parts of the U.S. including Texas, Arizona, and Colorado.
  • Jan-2021: Myriad Genetics teamed up with Illumina, a company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Through this collaboration, Illumina is expected to develop a kit-based version of the myChoice companion diagnostic (CDx) test for international markets. The collaboration is expected to integrate companion diagnostics and next-generation sequencing to expedite comprehensive genomic profiling of tumor samples and boost enhanced results in oncology.

Acquisitions and Mergers:

  • Aug-2021: BioReference Laboratories took over Ariosa's centralized laboratory prenatal testing business of the US from Roche. The acquisition is expected to help BioReference Laboratories' NIPS offerings and further increase its focus on prenatal screening, enabling BioReference and GenPath to develop high-quality and accessible testing that enhances medical care and results of patients and their families.
  • Aug-2021: Fulgent Genetics completed the acquisition of CSI Laboratories, a patient-focused model of cancer diagnostic testing for pathologists, community hospitals, and their patients. The acquisition aimed to help CSI substantially expand its capabilities in molecular diagnostics and oncologic testing. Moreover, Fulgent is expected to harness the potential of its established technology platform, lab operations, NGS expertise, and sales infrastructure along with CSI’s broad cancer testing capabilities to set up a differentiated foothold in oncologic testing across the US.
  • Aug-2021: Illumina acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers. Through this acquisition, the company aimed to expedite access and adoption of this life-saving test across the world.
  • Jun-2021: Eurofins Clinical Testing US, a subsidiary of Eurofins Scientific, signed an agreement to acquire DNA Diagnostics Center, the leading provider of DNA and paternity testing. Through this acquisition, the company aimed to expedite its vision to enter into a consumer genetic testing segment that supports customized lifestyle and health awareness.
  • Jan-2020: Quest Diagnostics completed the acquisition of Blueprint Genetics, a company that provides complete genetic testing and genetic diagnostics to medical professionals around the world. Following the acquisition, the two companies is expected to increase access to valuable insights in genetic and rare diseases, enhancing patient care and pharmaceutical drug research and development.

Product Launches and Product Expansions:

  • Sep-2021: Sema4 launched Sema4 Elements, a line of information-driven genomic solutions, digital tools for patients and vendors, and services that allow vendors to treat patients holistically throughout their reproductive and generational health journey. The product line of the Sema4 Elements portfolio includes solutions for the diagnosis, treatment, and management of preventive, reproductive, and family care.
  • Aug-2020: Quest Diagnostics rolled out AncestryHealth with the help of its Ancestry, a rapid and cost-effective way to carry out next-generation sequencing (NGS). Through this launch, company aimed to offer a genetic screening of risks for an expanded set of health conditions like heart disease, colon cancer, breast cancer, and blood disorders.
  • Feb-2020: Thermo Fisher Scientific launched a new next-generation sequencing (NGS)-based solution. Through this solution, the company is expected to allow reproductive health researchers to more effectively examine a wide range of key genetic markers with an end-to-end workflow. The CarrierSeq ECS Kit comprises a 420-gene, AmpliSeq-based panel that integrates various stand-alone tests into a single assay.

Scope of the Study

Market Segments Covered in the Report:


By Type


  • Expanded Carrier Screening and
  • Targeted Disease Carrier Screening

By Technology


  • DNA Sequencing
  • Microarrays
  • Polymerase Chain Reaction and
  • Other technology

By End User


  • Hospital and Clinics
  • Physician Offices
  • Reference Laboratories and
  • Other End Users

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:


  • Quest Diagnostics, Incorporated
  • Thermo Fisher Scientific
  • Illumina, Inc.
  • Eurofins Scientific Group
  • Invitae Corporation
  • OPKO Health, Inc.
  • Fulgent Genetics
  • Sema4 OpCo, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Carrier Screening Market, by Type
1.4.2 Global Carrier Screening Market, by Technology
1.4.3 Global Carrier Screening Market, by End User
1.4.4 Global Carrier Screening Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions: 2017, Jun - 2021, Jun) Leading Players
Chapter 4. Global Carrier Screening Market by Type
4.1 Global Expanded Carrier Screening Market by Region
4.2 Global Targeted Disease Carrier Screening Market by Region
4.3 Global Carrier Screening Market by Technology
4.4 Global DNA Sequencing Market by Region
4.5 Global Microarrays Market by Region
4.6 Global Polymerase Chain Reaction Market by Region
4.7 Global Other Technologies Market by Region
Chapter 5. Global Carrier Screening Market by End user
5.1 Global Hospital and Clinics Market by Region
5.2 Global Physician Offices Market by Region
5.3 Global Reference Laboratories Market by Region
5.4 Global Other End user Market by Region
Chapter 6. Global Carrier Screening Market by Region
6.1 North America Carrier Screening Market
6.1.1 North America Carrier Screening Market by Type
6.1.1.1 North America Expanded Carrier Screening Market by Country
6.1.1.2 North America Targeted Disease Carrier Screening Market by Country
6.1.2 North America Carrier Screening Market by Technology
6.1.2.1 North America DNA Sequencing Market by Country
6.1.2.2 North America Microarrays Market by Country
6.1.2.3 North America Polymerase Chain Reaction Market by Country
6.1.2.4 North America Other Technologies Market by Country
6.1.3 North America Carrier Screening Market by End user
6.1.3.1 North America Hospital and Clinics Market by Country
6.1.3.2 North America Physician Offices Market by Country
6.1.3.3 North America Reference Laboratories Market by Country
6.1.3.4 North America Other End user Market by Country
6.1.4 North America Carrier Screening Market by Country
6.1.4.1 USA Carrier Screening Market
6.1.4.1.1 USA Carrier Screening Market by Type
6.1.4.1.2 USA Carrier Screening Market by Technology
6.1.4.1.3 USA Carrier Screening Market by End user
6.1.4.2 Canada Carrier Screening Market
6.1.4.2.1 Canada Carrier Screening Market by Type
6.1.4.2.2 Canada Carrier Screening Market by Technology
6.1.4.2.3 Canada Carrier Screening Market by End user
6.1.4.3 Mexico Carrier Screening Market
6.1.4.3.1 Mexico Carrier Screening Market by Type
6.1.4.3.2 Mexico Carrier Screening Market by Technology
6.1.4.3.3 Mexico Carrier Screening Market by End user
6.1.4.4 Rest of North America Carrier Screening Market
6.1.4.4.1 Rest of North America Carrier Screening Market by Type
6.1.4.4.2 Rest of North America Carrier Screening Market by Technology
6.1.4.4.3 Rest of North America Carrier Screening Market by End user
6.2 Europe Carrier Screening Market
6.2.1 Europe Carrier Screening Market by Type
6.2.1.1 Europe Expanded Carrier Screening Market by Country
6.2.1.2 Europe Targeted Disease Carrier Screening Market by Country
6.2.2 Europe Carrier Screening Market by Technology
6.2.2.1 Europe DNA Sequencing Market by Country
6.2.2.2 Europe Microarrays Market by Country
6.2.2.3 Europe Polymerase Chain Reaction Market by Country
6.2.2.4 Europe Other Technologies Market by Country
6.2.3 Europe Carrier Screening Market by End user
6.2.3.1 Europe Hospital and Clinics Market by Country
6.2.3.2 Europe Physician Offices Market by Country
6.2.3.3 Europe Reference Laboratories Market by Country
6.2.3.4 Europe Other End user Market by Country
6.2.4 Europe Carrier Screening Market by Country
6.2.4.1 Germany Carrier Screening Market
6.2.4.1.1 Germany Carrier Screening Market by Type
6.2.4.1.2 Germany Carrier Screening Market by Technology
6.2.4.1.3 Germany Carrier Screening Market by End user
6.2.4.2 UK Carrier Screening Market
6.2.4.2.1 UK Carrier Screening Market by Type
6.2.4.2.2 UK Carrier Screening Market by Technology
6.2.4.2.3 UK Carrier Screening Market by End user
6.2.4.3 France Carrier Screening Market
6.2.4.3.1 France Carrier Screening Market by Type
6.2.4.3.2 France Carrier Screening Market by Technology
6.2.4.3.3 France Carrier Screening Market by End user
6.2.4.4 Russia Carrier Screening Market
6.2.4.4.1 Russia Carrier Screening Market by Type
6.2.4.4.2 Russia Carrier Screening Market by Technology
6.2.4.4.3 Russia Carrier Screening Market by End user
6.2.4.5 Spain Carrier Screening Market
6.2.4.5.1 Spain Carrier Screening Market by Type
6.2.4.5.2 Spain Carrier Screening Market by Technology
6.2.4.5.3 Spain Carrier Screening Market by End user
6.2.4.6 Italy Carrier Screening Market
6.2.4.6.1 Italy Carrier Screening Market by Type
6.2.4.6.2 Italy Carrier Screening Market by Technology
6.2.4.6.3 Italy Carrier Screening Market by End user
6.2.4.7 Rest of Europe Carrier Screening Market
6.2.4.7.1 Rest of Europe Carrier Screening Market by Type
6.2.4.7.2 Rest of Europe Carrier Screening Market by Technology
6.2.4.7.3 Rest of Europe Carrier Screening Market by End user
6.3 Asia Pacific Carrier Screening Market
6.3.1 Asia Pacific Carrier Screening Market by Type
6.3.1.1 Asia Pacific Expanded Carrier Screening Market by Country
6.3.1.2 Asia Pacific Targeted Disease Carrier Screening Market by Country
6.3.2 Asia Pacific Carrier Screening Market by Technology
6.3.2.1 Asia Pacific DNA Sequencing Market by Country
6.3.2.2 Asia Pacific Microarrays Market by Country
6.3.2.3 Asia Pacific Polymerase Chain Reaction Market by Country
6.3.2.4 Asia Pacific Other Technologies Market by Country
6.3.3 Asia Pacific Carrier Screening Market by End user
6.3.3.1 Asia Pacific Hospital and Clinics Market by Country
6.3.3.2 Asia Pacific Physician Offices Market by Country
6.3.3.3 Asia Pacific Reference Laboratories Market by Country
6.3.3.4 Asia Pacific Other End user Market by Country
6.3.4 Asia Pacific Carrier Screening Market by Country
6.3.4.1 China Carrier Screening Market
6.3.4.1.1 China Carrier Screening Market by Type
6.3.4.1.2 China Carrier Screening Market by Technology
6.3.4.1.3 China Carrier Screening Market by End user
6.3.4.2 Japan Carrier Screening Market
6.3.4.2.1 Japan Carrier Screening Market by Type
6.3.4.2.2 Japan Carrier Screening Market by Technology
6.3.4.2.3 Japan Carrier Screening Market by End user
6.3.4.3 India Carrier Screening Market
6.3.4.3.1 India Carrier Screening Market by Type
6.3.4.3.2 India Carrier Screening Market by Technology
6.3.4.3.3 India Carrier Screening Market by End user
6.3.4.4 South Korea Carrier Screening Market
6.3.4.4.1 South Korea Carrier Screening Market by Type
6.3.4.4.2 South Korea Carrier Screening Market by Technology
6.3.4.4.3 South Korea Carrier Screening Market by End user
6.3.4.5 Singapore Carrier Screening Market
6.3.4.5.1 Singapore Carrier Screening Market by Type
6.3.4.5.2 Singapore Carrier Screening Market by Technology
6.3.4.5.3 Singapore Carrier Screening Market by End user
6.3.4.6 Malaysia Carrier Screening Market
6.3.4.6.1 Malaysia Carrier Screening Market by Type
6.3.4.6.2 Malaysia Carrier Screening Market by Technology
6.3.4.6.3 Malaysia Carrier Screening Market by End user
6.3.4.7 Rest of Asia Pacific Carrier Screening Market
6.3.4.7.1 Rest of Asia Pacific Carrier Screening Market by Type
6.3.4.7.2 Rest of Asia Pacific Carrier Screening Market by Technology
6.3.4.7.3 Rest of Asia Pacific Carrier Screening Market by End user
6.4 LAMEA Carrier Screening Market
6.4.1 LAMEA Carrier Screening Market by Type
6.4.1.1 LAMEA Expanded Carrier Screening Market by Country
6.4.1.2 LAMEA Targeted Disease Carrier Screening Market by Country
6.4.2 LAMEA Carrier Screening Market by Technology
6.4.2.1 LAMEA DNA Sequencing Market by Country
6.4.2.2 LAMEA Microarrays Market by Country
6.4.2.3 LAMEA Polymerase Chain Reaction Market by Country
6.4.2.4 LAMEA Other Technologies Market by Country
6.4.3 LAMEA Carrier Screening Market by End user
6.4.3.1 LAMEA Hospital and Clinics Market by Country
6.4.3.2 LAMEA Physician Offices Market by Country
6.4.3.3 LAMEA Reference Laboratories Market by Country
6.4.3.4 LAMEA Other End user Market by Country
6.4.4 LAMEA Carrier Screening Market by Country
6.4.4.1 Brazil Carrier Screening Market
6.4.4.1.1 Brazil Carrier Screening Market by Type
6.4.4.1.2 Brazil Carrier Screening Market by Technology
6.4.4.1.3 Brazil Carrier Screening Market by End user
6.4.4.2 Argentina Carrier Screening Market
6.4.4.2.1 Argentina Carrier Screening Market by Type
6.4.4.2.2 Argentina Carrier Screening Market by Technology
6.4.4.2.3 Argentina Carrier Screening Market by End user
6.4.4.3 UAE Carrier Screening Market
6.4.4.3.1 UAE Carrier Screening Market by Type
6.4.4.3.2 UAE Carrier Screening Market by Technology
6.4.4.3.3 UAE Carrier Screening Market by End user
6.4.4.4 Saudi Arabia Carrier Screening Market
6.4.4.4.1 Saudi Arabia Carrier Screening Market by Type
6.4.4.4.2 Saudi Arabia Carrier Screening Market by Technology
6.4.4.4.3 Saudi Arabia Carrier Screening Market by End user
6.4.4.5 South Africa Carrier Screening Market
6.4.4.5.1 South Africa Carrier Screening Market by Type
6.4.4.5.2 South Africa Carrier Screening Market by Technology
6.4.4.5.3 South Africa Carrier Screening Market by End user
6.4.4.6 Nigeria Carrier Screening Market
6.4.4.6.1 Nigeria Carrier Screening Market by Type
6.4.4.6.2 Nigeria Carrier Screening Market by Technology
6.4.4.6.3 Nigeria Carrier Screening Market by End user
6.4.4.7 Rest of LAMEA Carrier Screening Market
6.4.4.7.1 Rest of LAMEA Carrier Screening Market by Type
6.4.4.7.2 Rest of LAMEA Carrier Screening Market by Technology
6.4.4.7.3 Rest of LAMEA Carrier Screening Market by End user
Chapter 7. Company Profiles
7.1 Quest Diagnostics, Incorporated
7.1.1 Company Overview
7.1.1 Financial Analysis
7.1.2 Recent strategies and developments:
7.1.2.1 Partnerships, Collaborations, and Agreements:
7.1.2.2 Product Launches and Product Expansions:
7.1.2.3 Acquisition and Mergers:
7.2 Thermo Fisher Scientific, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.2.6 SWOT Analysis
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.3.5.2 Acquisition and Mergers:
7.4 Eurofins Scientific Group
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Partnerships, Collaborations, and Agreements:
7.4.4.2 Acquisition and Mergers:
7.5 Invitae Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Product Launches and Product Expansions:
7.5.5.2 Acquisition and Mergers:
7.6 OPKO Health, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Acquisition and Mergers:
7.7 Fulgent Genetics
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Acquisition and Mergers:
7.8 Sema4 OpCo, Inc.
7.8.1 Company Overview
7.8.2 Recent strategies and developments:
7.8.2.1 Partnerships, Collaborations, and Agreements:
7.8.2.2 Product Launches and Product Expansions:
7.9 Myriad Genetics, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Product Launches and Product Expansions:
7.1 Natera Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations, and Agreements:
7.10.5.2 Product Launches and Product Expansions:

Companies Mentioned

  • Quest Diagnostics, Incorporated
  • Thermo Fisher Scientific
  • Illumina, Inc.
  • Eurofins Scientific Group
  • Invitae Corporation
  • OPKO Health, Inc.
  • Fulgent Genetics
  • Sema4 OpCo, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.

Methodology

Loading
LOADING...